PH12020551404A1 - 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto - Google Patents
4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related theretoInfo
- Publication number
- PH12020551404A1 PH12020551404A1 PH12020551404A PH12020551404A PH12020551404A1 PH 12020551404 A1 PH12020551404 A1 PH 12020551404A1 PH 12020551404 A PH12020551404 A PH 12020551404A PH 12020551404 A PH12020551404 A PH 12020551404A PH 12020551404 A1 PH12020551404 A1 PH 12020551404A1
- Authority
- PH
- Philippines
- Prior art keywords
- therapeutic compositions
- halogen containing
- containing nucleotide
- uses related
- nucleoside therapeutic
- Prior art date
Links
- 229910052736 halogen Inorganic materials 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002777 nucleoside Substances 0.000 title abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 title abstract 2
- 239000002773 nucleotide Substances 0.000 title abstract 2
- 125000003729 nucleotide group Chemical group 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 201000009182 Chikungunya Diseases 0.000 abstract 2
- 208000004293 Chikungunya Fever Diseases 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 241000712892 Arenaviridae Species 0.000 abstract 1
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 abstract 1
- 201000005804 Eastern equine encephalitis Diseases 0.000 abstract 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 abstract 1
- 206010014587 Encephalitis eastern equine Diseases 0.000 abstract 1
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 abstract 1
- 206010014614 Encephalitis western equine Diseases 0.000 abstract 1
- 241000710781 Flaviviridae Species 0.000 abstract 1
- 241000150350 Peribunyaviridae Species 0.000 abstract 1
- 241000709664 Picornaviridae Species 0.000 abstract 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 abstract 1
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 abstract 1
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 abstract 1
- 201000005806 Western equine encephalitis Diseases 0.000 abstract 1
- 208000001455 Zika Virus Infection Diseases 0.000 abstract 1
- 208000035332 Zika virus disease Diseases 0.000 abstract 1
- 208000020329 Zika virus infectious disease Diseases 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639725P | 2018-03-07 | 2018-03-07 | |
| PCT/US2019/021168 WO2019173602A1 (en) | 2018-03-07 | 2019-03-07 | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12020551404A1 true PH12020551404A1 (en) | 2021-06-21 |
Family
ID=67846796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12020551404A PH12020551404A1 (en) | 2018-03-07 | 2020-09-07 | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210308168A1 (https=) |
| EP (1) | EP3762372A4 (https=) |
| JP (3) | JP7371931B2 (https=) |
| KR (2) | KR20200140274A (https=) |
| CN (2) | CN112074506B (https=) |
| AU (2) | AU2019231725B2 (https=) |
| BR (1) | BR112020018209A2 (https=) |
| CA (1) | CA3093222A1 (https=) |
| EA (1) | EA202092117A1 (https=) |
| GB (2) | GB2611644B (https=) |
| IL (1) | IL277160B2 (https=) |
| PH (1) | PH12020551404A1 (https=) |
| SG (1) | SG11202008527WA (https=) |
| WO (1) | WO2019173602A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| WO2020072931A2 (en) * | 2018-10-04 | 2020-04-09 | Octagon Therapeutics Inc. | Pre-activated nucleoside impdh inhibitors as anti-infective drugs |
| CN118477090A (zh) * | 2019-10-08 | 2024-08-13 | 埃默里大学 | 含4'-卤素的核苷酸和核苷治疗组合物以及其相关用途 |
| CA3176661A1 (en) * | 2020-04-24 | 2021-10-28 | Memorial Sloan-Kettering Cancer Center | Targeted therapy for the treatment & prevention of life-threatening complications of infection |
| US20240025938A1 (en) * | 2020-08-27 | 2024-01-25 | Emory University | Novel forms of antiviral nucleosides |
| CN114644666B (zh) * | 2020-12-18 | 2026-03-03 | 上海特化医药科技有限公司 | 5’-核苷前药的制备方法及中间体 |
| KR20230121622A (ko) * | 2020-12-18 | 2023-08-18 | 머크 샤프 앤드 돔 엘엘씨 | 항바이러스 뉴클레오시드의 합성 |
| CN112608357B (zh) * | 2020-12-21 | 2022-12-09 | 杭州科巢生物科技有限公司 | 一种抗病毒药物Molnupiravir的制备方法 |
| CN112778387A (zh) * | 2021-01-15 | 2021-05-11 | 杭州科巢生物科技有限公司 | 一种Molnupiravir晶型A及其制备方法 |
| WO2022174194A1 (en) * | 2021-02-15 | 2022-08-18 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2022174179A1 (en) * | 2021-02-15 | 2022-08-18 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| MX2023011870A (es) * | 2021-04-09 | 2023-12-07 | Univ Emory | Análogos de nucleósidos y de nucleótidos como agentes antivirales para coronavirus y otros virus. |
| US20240166680A1 (en) * | 2021-04-15 | 2024-05-23 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Nucleoside analog and use thereof |
| US11407779B1 (en) * | 2021-04-23 | 2022-08-09 | Divi's Laboratories Ltd. | Process for the preparation of molnupiravir |
| CN112979733B (zh) * | 2021-04-25 | 2021-09-10 | 南京颐媛生物医学研究院有限公司 | 抗乙肝病毒的化合物及其制备方法和应用 |
| US20250281519A1 (en) * | 2021-05-05 | 2025-09-11 | Emory University | Nucleotide and nucleoside therapeutic compositions, combinations and uses related thereto |
| CN113278040B (zh) * | 2021-06-16 | 2022-07-05 | 苏州立新制药有限公司 | 5’-异丁酰基-n4-羟基胞苷的制备方法 |
| CN117642410A (zh) * | 2021-06-18 | 2024-03-01 | 苏州春海生物医药有限公司 | N4-羟基胞苷的酯衍生物及其用途 |
| CA3226836A1 (en) | 2021-08-06 | 2023-02-09 | Intervet International B.V. | Method of treating veterinary viral diseases |
| CN118234862A (zh) | 2021-09-08 | 2024-06-21 | 阿利戈斯治疗公司 | 经修饰的短干扰核酸分子(siNA)及其用途 |
| CN113880902A (zh) * | 2021-10-26 | 2022-01-04 | 江苏睿实生物科技有限公司 | 一种Molnupiravir药物中间体及其制备方法 |
| US11541071B1 (en) * | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
| CN114478658A (zh) * | 2022-02-22 | 2022-05-13 | 苏州正济药业有限公司 | 一种莫那比拉韦的合成方法 |
| US20250282812A1 (en) * | 2022-04-20 | 2025-09-11 | Shanghai Institute Of Materia Medica , Chinese Academy Of Sciences | Antiviral nucleoside analogue, and pharmaceutical composition and use thereof |
| WO2024129985A2 (en) * | 2022-12-14 | 2024-06-20 | Lakewood Amedex, Inc. | Antiviral compounds, compositions, and uses thereof |
| IL321635A (en) | 2022-12-23 | 2025-08-01 | Meiji Seika Pharma Co Ltd | The aftermath of avermectin |
| WO2024182446A2 (en) | 2023-02-28 | 2024-09-06 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| US20240352464A1 (en) | 2023-03-07 | 2024-10-24 | Aligos Therapeutics, Inc. | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof |
| EP4705284A1 (en) * | 2023-05-05 | 2026-03-11 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CN117567310A (zh) * | 2023-11-28 | 2024-02-20 | 重庆智合生物医药有限公司 | 一种神经酰胺np1的合成方法 |
| WO2025144872A2 (en) * | 2023-12-29 | 2025-07-03 | Adarx Pharmaceuticals, Inc. | Nucleoside-derived lipids for drug delivery |
| WO2026011167A1 (en) * | 2024-07-05 | 2026-01-08 | Emory University | Thionucleosides as antiviral agents |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4207363A1 (de) * | 1992-03-04 | 1993-09-09 | Max Delbrueck Centrum | Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung |
| WO2004024185A1 (ja) * | 2002-09-11 | 2004-03-25 | Michio Ishibashi | 医薬または化粧料 |
| MX2009003403A (es) * | 2006-09-27 | 2009-04-09 | Coley Pharm Group Inc | Composiciones de ligandos de tlr y antivirales. |
| WO2009058800A2 (en) * | 2007-10-29 | 2009-05-07 | President And Fellows Of Harvard College | Synthesis of nucleosides |
| AU2009298802A1 (en) * | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| AU2012357940B2 (en) * | 2011-12-20 | 2017-02-16 | Riboscience Llc | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
| JP6165848B2 (ja) * | 2012-05-22 | 2017-07-19 | イデニク ファーマシューティカルズ エルエルシー | 肝疾患のためのｄ−アミノ酸化合物 |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| BR112015014457A2 (pt) * | 2012-12-21 | 2017-11-21 | Alios Biopharma Inc | composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c |
| EP2981542B1 (en) * | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
| JP6366693B2 (ja) | 2013-05-16 | 2018-08-01 | リボサイエンス・エルエルシー | ４’−フルオロ−２’−メチル置換ヌクレオシド誘導体 |
| AU2014302711A1 (en) * | 2013-06-26 | 2015-12-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP3052511A4 (en) * | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| WO2015054465A1 (en) | 2013-10-11 | 2015-04-16 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| MA40031A (fr) | 2014-06-24 | 2015-12-30 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| HUE051986T2 (hu) * | 2014-06-24 | 2021-04-28 | Janssen Biopharma Inc | Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| WO2016134056A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
| WO2016134054A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
| AU2016301188A1 (en) * | 2015-08-06 | 2018-02-15 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
| WO2017040892A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040896A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040895A1 (en) | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017165489A1 (en) * | 2016-03-23 | 2017-09-28 | Emory University | Antiviral agents for treating zika and dengue virus infections |
| EP3471738A4 (en) * | 2016-06-20 | 2020-01-01 | Merck Sharp & Dohme Corp. | CYCLIC PHOSPHONATE-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR USE THEREOF FOR TREATING VIRUS DISEASES |
-
2019
- 2019-03-07 KR KR1020207028655A patent/KR20200140274A/ko not_active Ceased
- 2019-03-07 CN CN201980030574.4A patent/CN112074506B/zh active Active
- 2019-03-07 GB GB2218405.5A patent/GB2611644B/en active Active
- 2019-03-07 IL IL277160A patent/IL277160B2/en unknown
- 2019-03-07 JP JP2020546962A patent/JP7371931B2/ja active Active
- 2019-03-07 BR BR112020018209-5A patent/BR112020018209A2/pt active Search and Examination
- 2019-03-07 CN CN202411351705.8A patent/CN119633010A/zh active Pending
- 2019-03-07 EA EA202092117A patent/EA202092117A1/ru unknown
- 2019-03-07 EP EP19764729.0A patent/EP3762372A4/en active Pending
- 2019-03-07 AU AU2019231725A patent/AU2019231725B2/en active Active
- 2019-03-07 KR KR1020267004999A patent/KR20260028884A/ko active Pending
- 2019-03-07 US US16/979,108 patent/US20210308168A1/en not_active Abandoned
- 2019-03-07 GB GB2015827.5A patent/GB2589205B/en active Active
- 2019-03-07 WO PCT/US2019/021168 patent/WO2019173602A1/en not_active Ceased
- 2019-03-07 SG SG11202008527WA patent/SG11202008527WA/en unknown
- 2019-03-07 CA CA3093222A patent/CA3093222A1/en active Pending
-
2020
- 2020-09-07 PH PH12020551404A patent/PH12020551404A1/en unknown
-
2023
- 2023-07-26 US US18/359,435 patent/US20240180948A1/en active Pending
- 2023-10-12 JP JP2023176993A patent/JP7786743B2/ja active Active
-
2024
- 2024-09-19 AU AU2024219862A patent/AU2024219862A1/en active Pending
-
2025
- 2025-11-27 JP JP2025207111A patent/JP2026062641A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL277160B2 (en) | 2024-10-01 |
| EP3762372A4 (en) | 2021-12-08 |
| GB202218405D0 (en) | 2023-01-18 |
| AU2019231725B2 (en) | 2024-06-20 |
| CN119633010A (zh) | 2025-03-18 |
| AU2024219862A1 (en) | 2024-10-10 |
| US20240180948A1 (en) | 2024-06-06 |
| IL277160A (en) | 2020-10-29 |
| US20210308168A1 (en) | 2021-10-07 |
| JP2026062641A (ja) | 2026-04-10 |
| CN112074506A (zh) | 2020-12-11 |
| RU2020132881A (ru) | 2022-04-12 |
| JP7786743B2 (ja) | 2025-12-16 |
| CN112074506B (zh) | 2024-10-11 |
| GB2611644B (en) | 2023-07-26 |
| WO2019173602A1 (en) | 2019-09-12 |
| JP2021517132A (ja) | 2021-07-15 |
| GB2589205B (en) | 2023-05-24 |
| AU2019231725A1 (en) | 2020-10-08 |
| CA3093222A1 (en) | 2019-09-12 |
| EP3762372A1 (en) | 2021-01-13 |
| SG11202008527WA (en) | 2020-10-29 |
| EA202092117A1 (ru) | 2021-06-28 |
| JP2024009953A (ja) | 2024-01-23 |
| GB202015827D0 (en) | 2020-11-18 |
| IL277160B1 (en) | 2024-06-01 |
| KR20260028884A (ko) | 2026-03-04 |
| GB2611644A (en) | 2023-04-12 |
| BR112020018209A2 (pt) | 2020-12-29 |
| GB2589205A (en) | 2021-05-26 |
| JP7371931B2 (ja) | 2023-10-31 |
| KR20200140274A (ko) | 2020-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551404A1 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| WO2021137913A3 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| EP4491232A3 (en) | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | |
| PH12020550114A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| CN106573011A8 (zh) | 取代的核苷、核苷酸和其类似物 | |
| MX2024002353A (es) | Celulas asesinas naturales modificadas geneticamente. | |
| MY201997A (en) | Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof | |
| ZA202211060B (en) | Anti-viral compounds and methods for administration thereof | |
| CR20220082A (es) | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos | |
| ZA201908445B (en) | Recombinant adenoviruses carrying transgenes | |
| MX2022010874A (es) | Lactoferrina de uso oral con accion antiviral. | |
| JP2017070307A5 (https=) | ||
| DE69934885D1 (de) | Neue methoden und interferon defiziente substrate zur vermehrung von viren | |
| ZA202306360B (en) | Substituted pyridotriazine compounds and uses thereof | |
| DK1556021T3 (da) | Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger | |
| DE60142775D1 (de) | Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege | |
| MX2021011166A (es) | Polipeptidos que tienen actividad pululanasa adecuados para usarse en licuefaccion. | |
| DE60024100D1 (de) | Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen | |
| MX2018010958A (es) | Vacuna para virus de zika atenuado vivo. | |
| MX2018011205A (es) | Composiciones utiles en la prevencion y/o tratamiento de trastornos de la cavidad oral, vias aereas superiores y esofago. | |
| MX2015015781A (es) | Derivados de nucleósido 4'-azido, 3'-deoxi-3'-fluoro sustituido. | |
| CL2019000405A1 (es) | Vacunas virales. | |
| PH12022551990A1 (en) | Diamine-linked receptor-specific cyclic peptides | |
| MX2025013248A (es) | Composiciones terapéuticas de nucleótidos y nucleósidos que contienen 4'-halógeno y usos relacionados con estas | |
| EA202091005A1 (ru) | N4-гидроксицитидин и производные и связанные с этим противовирусные применения |